Stinson, T J <br/><br/>
Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients.  [electronic resource] 

 -  Cancer investigation  1999 
 - 559-65 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0735-7907 
<br/><br/><label>Standard No.: </label>10.3109/07357909909032840  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--economics<br/>Cisplatin--therapeutic use<br/>Costs and Cost Analysis<br/>Female<br/>Health Care Costs<br/>Humans<br/>Insurance, Health, Reimbursement<br/>Managed Care Programs<br/>Medicare--economics<br/>Neoplasm Recurrence, Local--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>United States